Royalty Pharma Stock Target Price and Analyst Consensus
| RPRX Stock | USD 33.02 0.25 0.76% |
The current analyst and expert consensus on Royalty Pharma is Strong Buy, with 4 strong buy opinions. The current projected Royalty Pharma target price consensus is 40.66 with 8 analyst opinions. Check out Macroaxis Advice on Royalty Pharma to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. The most common way Royalty Pharma Plc analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Royalty Pharma executives and customers to further validate their buy or sell advice. Note, the total number of analysts currently providing their opinion is not significant to determine adequate consensus on Royalty Pharma. We strongly encourage you to use your own analysis of Royalty Pharma Plc to validate this buy or sell advice. Royalty Pharma buy-or-sell recommendation module provides average expert sentiment on the projected Royalty Pharma Plc target price to derive its highest and lowest estimates based on projected price volatility of 1.8913.
Lowest Forecast 37 | Highest Forecast 45.13 | Target Price 40.66 |
Royalty |
It's important to approach Royalty Pharma's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Royalty Pharma Target Price Consensus
Royalty target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Royalty Pharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 8 | Strong Buy |
Most Royalty analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Royalty stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Royalty Pharma Plc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationRoyalty Pharma Target Price Projection
Royalty Pharma's current and average target prices are 33.02 and 40.66, respectively. The current price of Royalty Pharma is the price at which Royalty Pharma Plc is currently trading. On the other hand, Royalty Pharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Royalty Pharma Market Quote on 18th of March 2025
Target Price
Analyst Consensus On Royalty Pharma Target Price
Royalty Pharma Analyst Ratings
Royalty Pharma's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Royalty Pharma stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Royalty Pharma's financials, market performance, and future outlook by experienced professionals. Royalty Pharma's historical ratings below, therefore, can serve as a valuable tool for investors.Analyst Consensus Breakdown
Average Consensus Estimates
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize Royalty Pharma price targets
Royalty Pharma's stock target price is an estimate of its future price, usually made by analysts. Using Royalty Pharma's target price to determine if it is a suitable investment can be done through the following steps:- Look at Royalty Pharma's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if Royalty Pharma's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional Royalty Pharma Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of Royalty Pharma is a key component of Royalty Pharma valuation and have some predictive power on the future returns of a Royalty Pharma.Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | Macroaxis Index Invested few shares | |
 | Macroaxis Picks Invested few shares | |
 | Hedge Favorites Invested few shares | |
 | Artificial Intelligence Invested few shares | |
 | Warren Buffett Holdings Invested few shares | |
 | Momentum Invested over 60 shares | |
 | Adviser Favorites Invested few shares | |
 | SRI Sustainable Growth Invested over 40 shares | |
 | Apparel Invested over 40 shares | |
 | Casinos Sold over 90 shares | |
 | Utilities Invested over 90 shares | |
Additional Tools for Royalty Stock Analysis
When running Royalty Pharma's price analysis, check to measure Royalty Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Royalty Pharma is operating at the current time. Most of Royalty Pharma's value examination focuses on studying past and present price action to predict the probability of Royalty Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Royalty Pharma's price. Additionally, you may evaluate how the addition of Royalty Pharma to your portfolios can decrease your overall portfolio volatility.